Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

300.25 +12.07 (+4.19%)

Streaming Delayed Price Updated: 1:44 PM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity

August 03, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

PeptiDream Inks $2.2B Deal To Broaden Alnylam's siRNA Delivery Scope ↗

July 30, 2021

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and PeptiDream Inc have announced a license and collaboration agreement to discover and develop peptide-siRNA...

Via Benzinga

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues

July 29, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Alnylam's Lumasiran Substantially Reduces Plasma Oxalate Levels PH1 Patients With Severe Renal Impairment ↗

July 29, 2021

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in primary hyperoxaluria type 1 (...

Via Benzinga

Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

July 29, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results

July 21, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Stock Sees Healthy Rising Relative Strength Rating ↗

July 19, 2021

The Relative Strength (RS) Rating for Alnylam Pharmaceuticals stock climbed into a new percentile Monday, as it got a lift from 63 to 71.

Via Investor's Business Daily

The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay ↗

July 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,...

Via Benzinga

5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now ↗

July 01, 2021

Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.

Via The Motley Fool

Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension

June 30, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data ↗

July 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR ↗

June 28, 2021

Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion....

Via Benzinga

Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis

June 24, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway ↗

June 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Alnylam to Host Eighth Annual “RNAi Roundtable” Webcast Series

June 23, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

Via Talk Markets

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...

Via Benzinga

Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting

June 07, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy

June 01, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

May 26, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces New Advances in ATTR Amyloidosis Program

May 11, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming May Investor Conferences

May 04, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)

May 03, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript ↗

April 29, 2021

ALNY earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity

April 29, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran

April 19, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗

April 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...

Via Benzinga

The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗

April 24, 2021

Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.